Targeted cancer therapy (Q35953128)

11 August 2017

title

Targeted cancer therapy (English)

1 reference

11 August 2017

Charles Sawyers

1

1 reference

11 August 2017

publication date

1 November 2004

1 reference

11 August 2017

language of work or name

0 references

1 reference

11 August 2017

volume

432

1 reference

11 August 2017

issue

7015

1 reference

11 August 2017

page(s)

294-297

1 reference

publication type of scholarly work

11 August 2017

review article

1 reference

Opportunities and challenges in the development of kinase inhibitor therapy for cancer

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03095

7 January 2021

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03095

7 January 2021

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03095

7 January 2021

Lung cancer: intragenic ERBB2 kinase mutations in tumours

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03095

7 January 2021

Mutations of the BRAF gene in human cancer

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03095

7 January 2021

Mutational analysis of the tyrosine kinome in colorectal cancers

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03095

7 January 2021

High frequency of mutations of the PIK3CA gene in human cancers

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03095

7 January 2021

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03095

7 January 2021

Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03095

7 January 2021

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03095

7 January 2021

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03095

7 January 2021

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03095

7 January 2021

Overriding imatinib resistance with a novel ABL kinase inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03095

7 January 2021

Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/-)p53(-/-) mice

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03095

7 January 2021

A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03095

7 January 2021

Will mTOR inhibitors make it as cancer drugs?

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03095

7 January 2021

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03095

7 January 2021

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03095

7 January 2021

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03095

7 January 2021

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03095

7 January 2021

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03095

7 January 2021

Molecular basis of the VHL hereditary cancer syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03095

7 January 2021

TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03095

7 January 2021

Identifiers

DOI

10.1038/NATURE03095

1 reference

Dimensions Publication ID

11 August 2017

1010000533

0 references

1 reference